Same Indication

Nivolumab vs Sumatriptan

Nivolumab vs Sumatriptan: Overview

This comparison examines the pharmacological differences between Nivolumab and Sumatriptan.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Sumatriptan: Selective 5-HT1B/1D receptor agonist.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days; Sumatriptan β€” 2.5 hours.

Chemical Properties

Molecular Formula: Sumatriptan β€” C14H21N3O2S.

Molecular Weight: Sumatriptan β€” 295.4020 g/mol.

Type: Nivolumab β€” Antibody; Sumatriptan β€” Small molecule.